New Drug Combination Targets Undruggable Lung Cancer
Researchers have identified a synergistic drug combination that successfully targets KRAS-mutated non-small cell lung cancer (NSCLC), a variant historically classified as “undruggable.” By pairing experimental compounds with existing inhibitors, the ... Read More